🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccine schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the pandemic and has zeroed in on possible fatalities following Covid immunization in her brief tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Health officials had intended to announce sweeping changes to the pediatric immunization program in December, bringing the US with Denmark’s vaccine program, according to reports – a major change that would put the US out of alignment with many the global community with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

Instead of Vinay Prasad, Høeg is listed to address the audience at the meeting. She was just designated interim head of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A New Direction at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US to become more similar to Denmark, a society with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – traditionally the domain of Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Background

Høeg has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been typical for former heads of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Past directors of CBER would “understand legal statutes and the research of medication creation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that prior appointees who headed the center have had.”

CDER has an enormous workload at the agency, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership component to the position, which supervises in excess of 5,000 staff members. “It is a huge management job, if you execute it properly,” Woodcock added.

Response and Controversial Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among agency officials on immunizations, a press secretary responded that the “concerns are based on flawed presumptions”.

“Her experience is consistent with the responsibilities of her role,” the spokesperson explained, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed rapid medication authorization process that apparently troubled her preceding directors. “How are these medications being picked for this voucher program? Who takes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if problematic, track record, critics have noted. She authored a research paper using non-validated crowd-sourced reports to assess the frequency of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the current government featured revising rules for recently developed shots and discontinuing “non-essential” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing young men from getting Covid vaccines.

“She is an thorough dogmatist who commences with her beliefs and works backwards to retrofit the evidence in a highly deceptive, dishonest fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|